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Abstract
The synthetic psychostimulant MDMA (63,4-methylenedioxymethamphetamine, ecstasy) acts as an indirect serotonin,
dopamine, and norepinephrine agonist and as a mechanism-based inhibitor of the cytochrome P-450 2D6 (CYP2D6). It has
been suggested that women are more sensitive to MDMA effects than men but no clinical experimental studies have
satisfactorily evaluated the factors contributing to such observations. There are no studies evaluating the influence of
genetic polymorphism on the pharmacokinetics (CYP2D6; catechol-O-methyltransferase, COMT) and pharmacological
effects of MDMA (serotonin transporter, 5-HTT; COMT). This clinical study was designed to evaluate the pharmacokinetics
and physiological and subjective effects of MDMA considering gender and the genetic polymorphisms of CYP2D6, COMT,
and 5-HTT. A total of 27 (12 women) healthy, recreational users of ecstasy were included (all extensive metabolizers for
CYP2D6). A single oral weight-adjusted dose of MDMA was administered (1.4 mg/kg, range 75–100 mg) which was similar
to recreational doses. None of the women were taking oral contraceptives and the experimental session was performed
during the early follicular phase of their menstrual cycle. Principal findings show that subjects reached similar MDMA plasma
concentrations, and experienced similar positive effects, irrespective of gender or CYP2D6 (not taking into consideration
poor or ultra-rapid metabolizers) or COMT genotypes. However, HMMA plasma concentrations were linked to CYP2D6
genotype (higher with two functional alleles). Female subjects displayed more intense physiological (heart rate, and oral
temperature) and negative effects (dizziness, sedation, depression, and psychotic symptoms). Genotypes of COMT
val158met or 5-HTTLPR with high functionality (val/val or l/*) determined greater cardiovascular effects, and with low
functionality (met/* or s/s) negative subjective effects (dizziness, anxiety, sedation). In conclusion, the contribution of MDMA
pharmacokinetics following 1.4 mg/kg MDMA to the gender differences observed in drug effects appears to be negligible
or even null. In contrast, 5-HTTLPR and COMT val158met genotypes play a major role.
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Introduction
Ecstasy (63,4-methylenedioxymethamphetamine, MDMA) is a
synthetic psychostimulant derived from phenylethylamine and the
third most widely consumed illegal drug in the world [1]. This
increase in abuse has become a growing public health concern
since MDMA can produce acute toxicity and fatal episodes [2]. In
addition, its chronic consumption is associated with neurocognitive
deficits and increased psychopathology prevalence [3–6]. Several
studies suggest that women are more vulnerable to drug abuse
than males [7]. In some Western countries, female users present
higher rates of consumption and dependence on ecstasy than men
[1] and MDMA has been shown to produce stronger effects in
them [8,9]. Differences in drug disposition may contribute to this
observation; nevertheless, the only pharmacokinetic study pub-
lished to date does not have sufficient sample size to address this
issue [10].
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It has also been postulated that the genetic polymorphisms of
the serotonin transporter (5-HTT), catechol-O-methyltransferase
(COMT), and cytochrome P450 2D6 (CYP2D6), are implicated in
MDMA pharmacology as they may modulate both its pharma-
codynamics and pharmacokinetics in humans [11,12]. However,
these genotypes have not been examined in MDMA clinical
experimental pharmacology studies.
MDMA acts as an indirect serotonin (5-HT), norepinephrine
(NE), and dopamine (DA) agonist. Disposition of 5-HT and DA
at the synaptic cleft is modulated by the 5-HTT and the
COMT enzyme, respectively [13]. The most common genetic
variation of 5-HTT is the gene-linked polymorphic region (5-
HTTLPR) which presents two variants: the long (l) one which
results in a higher serotonin transporter mRNA transcription,
and the short (s) one which causes lower transcription [14]. The
COMT gene displays a functional polymorphism at codon 158
producing a valine (val) to methionine (met) substitution
(Val158Met, rs4680) resulting in three genotypes (val/val, val/
met, and met/met). Individuals with the met allele have a lower
enzyme activity which leads to higher levels of extracellular
dopamine [15].
The main metabolic pathway of MDMA in humans is its O-
demethylenation to 3,4-dihydroxymethamphetamine (HHMA) by
the CYP2D6, followed by the O-methylation of HHMA to 4-
hydroxy-3-methoxymethamphetamine (HMMA) by COMT.
CYP2D6 displays a large genetic variability determined by the
number of functional alleles (FA). In 70–80% of Caucasians the
most prevalent phenotype of CYP2D6 is the extensive metab-
olizer (EM) [16]. The clinical implications derived from CYP2D6
genetic polymorphisms are a large variability of MDMA plasma
concentrations and, as a consequence, a difference in drug
response, adverse effects [12], and the bioactivation of MDMA
to putative neurotoxic species in humans [17]. MDMA is also a
potent inhibitor of CYP2D6 through the formation of a
metabolic inhibitory complex [18–21]. This is of relevance since
MDMA can temporarily (approximately ten days) convert EM
subjects to apparently poor metabolizers (PM) [22,23] thus
increasing the risk of toxicity of other substances whose
disposition is regulated by CYP2D6 [16].
Since the contributing factors for the observation of gender
differences in MDMA induced effects have not been satisfactorily
determined, and that there are no previously published reports
about the influence of CYP2D6, COMT val158met, and 5-HTTLPR
genotypes on its pharmacokinetics and pharmacodynamics, the
present study will examine both the impact of gender and genetics
on the clinical pharmacology of MDMA.
Materials and Methods
Participants
Subjects were recruited by word of mouth and gave their
written informed consent before inclusion in the study. Inclusion
criteria were: healthy male and female adults, the recreational
use of MDMA on at least ten occasions (two in the previous
year), and the EM phenotype for CYP2D6 activity determined
using dextromethorphan as a selective probe drug [23]. Women
had to present a regular menstrual cycle and not be taking oral
contraceptives. Exclusion criteria included daily consumption
.20 cigarettes and .4 standard units of ethanol in men (.2 in
women), and regular ingestion of medication in the month
preceding the study. Eligible subjects underwent a psychiatric
interview (Psychiatric Research Interview for Substance and
Mental Disorders –PRISM) [24] to exclude the presence of
major psychiatric disorders, history of abuse or drug depen-
dence (except for nicotine dependence), and psychiatric adverse
reactions after MDMA consumption. To confirm health status,
volunteers were interviewed by a physician and underwent a
general physical examination, routine laboratory tests, urinalysis,
and a 12-lead electrocardiogram (ECG). All subjects were
informed about the possible adverse effects during the study and
were financially compensated for any inconvenience derived
from their participation.
Test Procedure
The design was open as the primary outcomes measured
(pharmacokinetics) were objective. Subjects participated as outpa-
tients, women during early follicular phase, in a session that began
at 7:30 a.m. in fasting conditions. Participants were requested to
refrain from consuming any illicit drug of abuse for 2 weeks before
the experimental session and were asked to follow a xanthine-free
diet and alcohol-free ingestion 48 and 24 hours, respectively, prior
to the beginning of each session. Before drug administration, urine
samples were collected for a drug screen (opiates, cocaine
metabolite, amphetamine, methamphetamine, cannabinoids, and
phencyclidine) by a quick on-site test (Instant-View; ASD Inc.,
Poway, California, USA), and for pregnancy testing in females.
Negative results were mandatory for participation in the session.
Single doses of medication for symptomatic treatment (e.g.
acetaminophen for headache) were accepted up to the week
preceding the trial. An indwelling catheter was inserted into a
subcutaneous vein in the forearm of the non-dominant arm to
obtain blood samples. Thereafter, the subjects remained seated in
a quiet room. Drug administration commenced at 8:30 a.m. with
250 mL of water, and a light breakfast was provided 2 h later.
Tobacco smoking was permitted after lunch (6 h after MDMA
administration). A psychiatrist evaluated volunteers 10 hours after
MDMA administration. As the experimental session lasted 25
hours, subjects were admitted to the Clinical Research Unit for the
night. Adverse events and concomitant medications were record-
ed.
Drugs
Doses of MDMA were chosen according to data from previous
studies [25,21] and were within the range of the recreational doses
reported for a single tablet of ecstasy. For the security of the
volunteers, mainly the women, a 1.4 mg/kg of MDMA was
administered (range, 75–100 mg). (R,S)-MDMA was supplied by
the Spanish Ministry of Health and prepared in white, opaque,
soft gelatin capsules by the Pharmacy Department of the Hospital
del Mar (Barcelona, Spain).
Pharmacokinetic Measurements
For determination of MDMA and metabolites, blood samples
(8 mL) were collected at pre-dose, and at 0.33, 0.66, 1, 1.5, 2, 4, 6,
8, 10, 12, 25, and 48 hours after MDMA administration. Blood
was collected in heparinized tubes and then centrifuged at 4uC for
10 min. The resulting four 1-mL plasma aliquots were stored at
220uC until analysis. MDMA, HMMA MDA (3,4-methylene-
dioxyamphetamine), and HMA (3-methoxy-4-hydroxyamphet-
amine) were analyzed following a previously reported method
based on solid-liquid extraction and gas chromatography–mass
spectrometry (GC/MS) [26].
Genotyping
Genomic DNA was extracted from the peripheral blood
leukocytes of participants using the Flexi Gene DNA kit (Qiagen
Iberia, S.L., Spain). The COMT val108/158met and 5-HTTLPR
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genotyping was performed using polymerase chain reaction (PCR)
as previously described [27]. The CYP2D6 genotypes were
determined using the PHARMAchipTM DNA array (Progenika
Biopharma, Derio, Spain) [28]. Subjects were split according to
genotype and associated functionality (CYP2D6, carrying 1 or 2
FA; COMT val158met, carrying the val/val or met/* alleles; and 5-
HTTLPR, carrying the l/* or s/s alleles) in order to have
equilibrated groups for comparisons, considering genotypes and
genders separately.
Physiological Measures
Readings of non-invasive systolic blood pressure (SBP), diastolic
blood pressure (DBP), heart rate (HR), oral temperature (OT),
pupil diameter (PD), and esophoria (ESO) were taken 15 minutes
prior to drug administration, at baseline (time 0), and at 0.33, 0.66,
1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours after drug
administration. SBP, DBP, HR, and OT were recorded using a
CarescapeTM V100 monitor (GE Healthcare. Milwaukee, WI).
Pupil diameter was calculated using a pupil gauge (Haab scale).
The Maddox-wing device (AM, Clement Clark, London, U.K)
was used to measure the balance of extraocular muscles and
quantify exophoria and esophoria (MDMA effect) [25]. For safety
reasons, ECG was continuously monitored during the first 12 h
with a DashH 3000 patient monitor (GE Healthcare).
Rating Scales of Subjective Effects
Subjective effects were measured using a set of visual analogue
scales (VAS), the Addiction Research Center Inventory (ARCI),
and the Evaluation of the Subjective Effects of Substances with
Abuse Potential (VESSPA) questionnaire at baseline and at 0.33*,
0.66*, 1, 1.5*, 2, 3, 4, 5, 6, 8, 10, 12, and 24 h (* only VAS) after
MDMA administration. VAS. Twenty one 100-mm VAS labeled
with different adjectives marked at opposite ends with ‘‘not at all’’
and ‘‘extremely’’ were administered [29]. ARCI. A Spanish
validated version of a 49-item short form of ARCI was used
[29,30]. VESSPA is a validated questionnaire measuring MDMA-
induced changes in subjective variables [30].
Ethics
The study was approved by the local Ethics Committee (CEIC-
Parc de Salut Mar), authorized by the Spanish Medicine Agency
(AEMPS nu. 04–0013) of the Spanish Ministry of Health, and was
conducted in accordance with the Declaration of Helsinki
(Edinburgh, 2000) and good clinical practices. The study was
registered at ClinicalTrials.gov (NCT01447472). Subjects gave
their written informed consent before inclusion in the study.
Statistical Analyses
A description of both male and female volunteers is given with
means, standard deviations, and ranges (min and max values).
Values of the peak plasma concentration (Cmax) of MDMA and its
metabolites, and the time to reach Cmax (Tmax), were obtained
directly from the plasma concentration-time profiles of MDMA,
MDA, HHMA, and HMA. Area under the concentration-time
curve values (AUC) was calculated using the trapezoidal rule.
Absorption and elimination rate constant (Ka and Ke, respectively)
were estimated by log-linear regression of initial and four terminal
data points. Values from physiological measures and subjective
variables were transformed to differences from baseline and their
peak effect (Emax), Tmax and AUC were calculated from effect-time
profiles. The x2-square test was used to check for the Hardy-
Weinberg equilibrium.
To study gender differences with respect to pharmacokinetic
(Cmax, AUC, Tmax, T1/2, ratio MDMA/HMMA), physiological,
and subjective effect parameters (Emax, AUC, Tmax), ANCOVA
models were used including both gender and weight-adjusted dose
as independent variables. In addition, the possible effect of the
COMT val158met and CYP2D6 genotypes on the plasma concen-
tration of MDMA, MDA, HHMA, and HMA was analyzed using
separate ANCOVA models for genotypes as well as gender and
weight-adjusted dose as further independent variables. Concerning
pharmacodynamic variables, separate ANCOVA models, includ-
ing gender and weight-adjusted dose, were applied to study the
role of COMT val158met and 5-HTTLPR, respectively. Due to the
small sample size, instead of including the respective interaction
terms in the ANCOVA models, separate nonparametric Wilcoxon
tests comparing males with females were carried out for each
genotype. Differences were considered to be significant if p,0.05.
Statistical analyses were performed with the statistical software
packages SPSS 12.0 for Windows (SPSS, Inc., 2003) and R,
version 2.13.1 (The R Foundation for Statistical Computing). Data
resulting from the ANCOVA model are presented with the p value
and the 95% confidence interval of the mean difference between
genders or genotypes.
Results
Sample Characteristics and Doses
A total of 45 Caucasian subjects [26 women (W), 19 men (M)]
were recruited, but only 27 (12 W, 15 M) were included and
completed the study. The reasons for the volunteers’ exclusion
(n = 18) were: 12 W (10 having previous mental disorders [6 abuse
of/dependence on drugs of abuse; 4 affective disorders]), 1
CYP2D6 PM phenotype, and 1 due to a positive drug screen test
for cannabis and cocaine); and 3 M (2 CYP2D6 PM phenotype,
and 1 with criteria of drug dependence). There were 3 withdrawals
(2 W, 1 M) before the experimental session due to personal
reasons.
The subjects included were tobacco smokers (10 W, 11 M), and
had previous experience using alcohol (all 27 subjects), cannabis
(8 W, 14 M), cocaine (6 W, 13 M), and gammahydroxybutirate
(GHB, 4 M). In Table 1 anthropometric data and the oral and
weight-adjusted MDMA doses are summarized according to
gender and genotypes. Weight, height, and total MDMA dose
administered were higher in men than in women, but body mass
index was similar in both genders. According to genotypes, few
differences were observed in MDMA doses in the distribution of
gender and anthropometric data among the subgroups, age,
however, varied in the 5-HTTLPR genotype subgroups. Gender,
genotypes, and the MDMA doses administered for each partic-
ipant are specified in Table 2. The COMT (p= 0.44) but not the 5-
HTTLPR (p= 0.018) genotype fulfill the Hardy-Weinberg equilib-
rium.
Gender, genotypes, and the MDMA doses administered for
each participant are specified in Table 2.
Due to technical problems during analysis and/or not enough
sample volume for complete analysis, the data available from
pharmacokinetics and COMT genotype were for fewer subjects
than for pharmacodynamics (Tables 3, 3b, 4, 5).
Pharmacokinetics
Gender. No major gender differences were found for most of
the pharmacokinetic parameters evaluated for MDMA and its
metabolites (Table 3 and Figure 1). The only significant differences
observed concerned MDMA plasma clearance (Cl) and the
MDMA vs. HMMA AUC0–12 h ratio. Men presented a higher
Gender and Genetics on MDMA Clinical Pharmacology
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Cl compared to women (p= 0.001, 95% CI: 6.13–21.08); and
women displayed a higher MDMA vs. HMMA AUC0–12 h ratio
(p = 0.027, 95% CI: 0.14–2.12) than men.
CYP2D6 genotype. Subjects who were carriers of 2 FA of
CYP2D6 presented higher mean values in HMMA plasma
concentrations compared to volunteers with 1 FA [Cmax
(p = 0.003, 95% CI = 47.6–199.8), AUC0–4 h (p = 0.008, 95%
CI = 96.7–566.4) and AUC0–25 h (p = 0.003, 95% CI = 479.0–
2148.6)] (Table S1, and Figure 1).
COMT val158met genotype. Subjects who were carriers of
met/* alleles showed a higher mean MDMA Ke compared to val/
val individuals [p= 0.006, 95% CI = 0.02–0.09] (Table S1).
Physiological Effects
MDMA produced the well-known physiological and subjective
effects described in the literature [29,21]. It increased BP, HR,
OT, PD, ESO and induced euphoria, stimulation, and well-being.
None of participants required specific therapy or special care due
to adverse events.
Gender. Women presented higher values than men in HR
[AUC 0–4 h (p= 0.009), AUC0–6 h (p = 0.013) and Emax
(p= 0.001)]; and OT [AUC 0–4 h (p= 0.038) and AUC0–6 h
(p = 0.017)] (Table 4 and Figure 2). Men showed a trend towards
significance in PD [AUC0–24 h (p = 0.057)].
COMT val158met genotype. The val/val allele carriers
presented higher values of SBP [AUC0–4 h (p= 0.012), AUC0–6 h
(p= 0.013), AUC0–24 h (p = 0.005) and Emax (p = 0.037,)] and DBP
[AUC0–24 h (p = 0.038)] compared to met/* ones (Table 5 and
Figure 2).
5-HTTLPR genotype. The l/* allele carriers presented
higher values of SBP [AUC0–4 h (p= 0.004), AUC0–6 h
(p= 0.004), AUC0–24 h (p = 0.022) and Emax (p = 0.002)]; DBP
[Emax (p= 0.009)]; and HR [AUC0–6 h (p= 0.017), AUC0–24 h
(p= 0.018), with a trend towards significance in Emax (p= 0.052)]
than s/s carriers (Table 5 and Figure 2).
Subjective Effects
Gender. Women displayed higher scores than men in VAS–
Dizziness [AUC0–4 h (p= 0.006) and AUC0–6 h (p= 0.005), AUC0–
24 h (p= 0.016), and Emax (p= 0.029)]; VAS–Depression or Sadness
[AUC0–6 h (p= 0.041) and Emax (p= 0.047)]; ARCI–PCAG Group
(sedation) [AUC0–24 h (p= 0.011) and Emax (p= 0.042)]; VESSPA–
Sedation [AUC0–4 h (p= 0.047), AUC0–6 h (p= 0.028), AUC0–24 h
(p= 0.005) and Emax (p= 0.002] (Table 4); and VESSPA-Psychotic
symptoms [AUC0–24 h (p= 0.048)].
COMT val158met genotype. The met/* allele carriers
presented higher response in VAS-Dizziness [AUC0–4 h
(p= 0.014), AUC0–6 h (p= 0.020), AUC0–24 h (p = 0.031) and Emax
(p = 0.022)], and VESSPA-ANX [AUC0–24 h (p = 0.025)] than val/
val carriers (Table 5).
5-HTTLPR genotype. The s/s allele carriers presented
higher values of VESSPA-Sedation [AUC0–4 h (p= 0.045)] in
relation to subjects with l/* alleles (Table 5).
No other differences according to gender and genetics were
observed in scales not previously discussed.
Discussion
To our knowledge, this is the first study on the human
pharmacology of MDMA that reports differences in pharmaco-
kinetics and physiological-subjective effects, taking into account
gender and genetics, after the administration of doses compatible
with its recreational consumption. We have confirmed that there
are marked gender differences in MDMA pharmacology: women
experienced heightened physiological effects, in particular,
cardiovascular ones. They also reported greater negative
subjective effects (e.g. dizziness, depression/sadness, and seda-
tion). These observations were not related to MDMA or MDA
pharmacokinetics as no major differences in their metabolic
disposition at the dose studied were reported between genders or
studied genotypes. In the studied population of extensive
Table 1. Anthropometric data of included volunteers and MDMA doses according to gender and genotypes (mean 6 SD [min,
max]).
Variable
Total dose p.o
(in mg)
Weight-adjusted dose
(in mg/kg) Age (in years) Weight (in Kg) Height (in cm) BMI (in kg/m2)
Gender
Men (n = 15) 95.367.4** [80, 100] 1.3660.1 [1.10, 1.51] 25.863.8 [19,33] 70.8610.8**
[54.2, 91.2]
181.068.0** [170.5,
195.5]
21.663.2 [17.2,
28.7]
Wome (n = 12) 79.565.4 [75, 90] 1.4260.05 [1.35, 1.50] 26.963.7 [21,35] 56.064.7
[50, 65.5]
166.764.8
[157.3, 173]
20.261.5 [17.5,
23.1]
Genotype
CYP2D6 - 1FA (n = 8) 88,8610,9 [75, 100] 1,3960,0 [1.27,1.45] 27.664.3 [22,35] 64.269.4
[52.9, 78.6]
175.167.8 [163.5,
184.0]
20.861.7 [19, 23.6]
CYP2D6–2FA (n = 19) 88,2610,3 [75, 100] 1,3960,1 [1.10, 1.51] 25.763.4 [19,31] 64.3612.3
[50, 91.2]
174.5610.8 [157.3,
195.5]
21.163.0 [17.2,
28.7]
COMT - val/val (n = 8) 84,4610,8 [75, 100] 1,3960,0 [1.20, 1.50] 26.064.2 [22,35] 61.1611.0
[50, 83.5]
170.569.5 [157.3,
190.0]
20.861.6 [19, 23.1]
COMT - met/* (n = 18) 90,869,4 [75, 100] 1,3860,1 [1.10, 1.51] 26.363.7 [19,33] 66.4611.4
[50, 91.2]
177.169.5 [161.2,
195.5]
21.263.1 [17.2,
28.7]
5-HTTLPR - l/* (n = 18) 88,9610,5 [75, 100] 1,3960,1 [1.12, 1.51] 27.663.2* [22,35] 64.7611.3
[50, 89]
174.9610.6 [157.3,
195.5]
21.162.5 [17.2,
28.7]
5-HTTLPR - s/s (n = 9) 87,269,3 [75, 100,] 1,3960,1 [1.10, 1.50] 23.863.6 [19,30] 63.6612.1
[50, 91.2]
174.268.8 [164.5, 194] 20.863.1 [17.5,
27.6]
MDMA, 63,4-methylenedioxymethamphetamine; CYP2D6, cytochrome P450 2D6; FA: functional alleles COMT, catechol-O-methyltransferase; 5-HTTLPR, gene-linked
polymorphic region. BMI: body mass index; p.o: per os. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0047599.t001
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metabolizers the CYP2D6 genotype was only relevant in the
plasmatic concentrations of HMMA depending on the carried
number of functional alleles. Furthermore, gender and COMT
val158met and 5-HTTLPR polymorphisms played a major role in
the physiological and subjective MDMA induced effects.
Genotypes corresponding to protein high functionality (e.g. 5-
HTTLPR l/* genotype or COMTval158met val/val genotype)
were associated with heightened cardiovascular effects.
Pharmacokinetics
The main findings are that women, when they received similar
weight-adjusted doses as men (1.4 mg/kg, but at a significantly
lower total dose, 80 mg vs. 95 mg), reached similar plasma
concentrations of MDMA and metabolites.
Our results partially differ from those of Kolbrich et al [10]
where a multiethnic group of 17 subjects (6 females) received low
(1.0 mg/kg) and high (1.6 mg/kg) oral MDMA doses in a double-
blind, randomized, placebo-controlled study. While our results are
similar to those reported by Kolbrich et al [10] at the high dose as
no gender differences were observed; in contrast, gender
differences were observed with the lower dose. This may be due
to the fact that at lower MDMA doses the impact of CYP2D6
autoinhibition in its metabolic disposition is less relevant than at
the higher ones. Secondly, discrepancies observed between our
study and Kolbrichs work could be due to differences in the power
of the sample size (n = 27 vs. n = 17), genetic polymorphisms of
CYP2D6, COMT, and 5-HTT (not measured in Kolbrich’s study),
Table 3. Gender differences in pharmacokinetic parameters of MDMA and its metabolites (mean 6 SD; for MDMA and HMMA:
women n= 11 vs. men n= 15; for MDA and HMA: women n= 11 vs. men n= 12).
AUC 0–25 h (mg?h?L
21) Cmax (mg/L) Tmax(h) T 1/2 (h) Ke (h
21) Ka (h
21) Vd (L) Cl (L/h/kg)
MDMA
Women 2667.16616.8 190.3660.7 2.661.4 11.0612.6 0.1060.05 2.2261.42 3756178 20.866.0
Men 2212.56649.7 187.5638.9 2.861.0 7.462.9 0.1160.04 2.7960.84 4786237 34.5612.0**
HMMA
Women 2460.461681.6 170.26131.5 3.662.8 15.569.9 0.0560.18 n.d n.d n.d
Men 2463.761081.5 190.1676.6 2.661.0 10.6610.9 0.1360.17 n.d n.d n.d
MDA
Women 290.4656.0 14.063.6 7.862.2 17.6610. 1 0.0260.13 n.d n.d n.d
Men 278.4661.5 13.363.4 6.363.3 11.9657.9 0.0160.05 n.d n.d n.d
HMA
Women 151.8680.3 6.263.2 8.163.5 n.d a n.d a n.d n.d n.d
Men 140.2665.9 6.062.5 7.562.7 n.d a n.d a n.d n.d n.d
MDMA, 63,4-methylenedioxymethamphetamine; MDA, 3,4-methylenedioxyamphetamine; HMA, 3-methoxy-4-hydroxyamphetamine; HMMA, 3-methoxy-4-
hydroxymethamphetamine; AUC: area under the concentration-time curve, Cmax: peak plasma concentration; Tmax: time with peak plasma; T1/2: half-life of elimination;
Ke: elimination constant; Ka: absorption constant; Vd: apparent volume of distribution; Cl: clearance; n.d: not determined, due to high variability (a).
**p,0.01.
doi:10.1371/journal.pone.0047599.t003
Table 4. Gender differences in physiological and subjective effects after MDMA administration (mean6 SD; women n= 12 vs. men
n= 15) (only significant effects included).
Outcomes AUC 0–4 h (Units) AUC 0–6 h (Units) AUC 0–24 h (Units) Emax (Units)
Women Men Women Men Women Men Women Men
Physiological measures
Heart rate 52.5616.0** 33.1628.5 69.3621.8* 41.7642.7 118.5681.0 62.26145.6 26.268.3** 15.1613.2
Oral temperature 1.260.8* 0.560.8 2.361.4* 1.161.1 6.465.7 3.763.5 0.660.4 0.460.5
Subjective effects
VAS – Dizziness 20.4617.0** 4.968.3 21.6617.6** 5.268.9 22.7618.4* 6.49612.1 17.7613.5* 6.169.6
VAS – Depression/Sadness 0.760.9 0.160.4 1.261.6* 0.160.4 2.264.9 0.1860.4 0.961.3* 0.160.3
ARCI – PCAG (Sedation) 6.569.0 0.468.5 9.2612.0 1.1610.1 30.5637.2* 1.8610.5 4.563.7* 0.464.2
VESSPA – Sedation 17.0612.2* 8.368.7 22.2615.0* 10.1610.3 54.4655.3** 10.7611.2 9.164.5** 3.963.6
VESSPA - Psychotic symptoms 6.664.0 4.165.6 7.864.5 4.466.0 9.266.7* 4.466.0 3.662.4 2.062.6
AUC: area under the effect-time curve; Emax: peak effect; Tmax: time of peak effect. VAS: visual analogue scale. ARCI: Addiction Research Center Inventory, PCAG:
pentobarbital-chlorpromazine-alcohol group. VESSPA: Evaluation of the Subjective Effects of Substances with Abuse Potential.
*p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0047599.t004
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and ethnicity that might have influenced the activity of these
proteins [31–33].
MDMA. Similar plasma concentrations in men and women
are consistent with Kolbrichs results at high dose [10]. Further-
more, our results in Ka and Vd are also in agreement with the
literature [18,10]. From a metabolic point of view, although oral
doses assayed reached the same level of CYP2D6 inhibition, men
80% and women 86% (p= 0.15) [18], the slightly higher MDMA
concentrations in women are most probably related to a lower
CYP2D6 baseline activity than men [22], and to a lower plasmatic
MDMA Cl.
According to the elimination parameters, men presented a
significantly higher MDMA Cl than women, but no gender
differences were observed in relation to Ke and T1/2. Variations in
Cl, although not determinant to generate gender differences in
MDMA plasma concentrations, could be due to the fact that the
Cl of drugs is generally higher in men than in women (25%)
[34,22,10]. In addition, the higher baseline CYP2D6 activity in
men would imply, despite the autoinhibition of the enzyme, a
greater capacity to clear the drug [22].
HMMA. Our results show that HMMA formation is condi-
tioned more by CYP2D6 polymorphism than by COMT
val158met. A higher CYP2D6 enzymatic activity (carriers of 2
FA) is determinant in HMMA plasma concentrations. In contrast,
the different enzymatic activity of COMT val158met genotype may
partially explain the inter-individual variability in susceptibility to
MDMA-induced neurotoxicity [17,20,35]. Finally, gender does
not appear to be relevant in HMMA formation, although men
tend to present greater concentrations because of the higher
activities of CYP2D6 and COMT [22,36], as reflected in the lower
MDMA vs. HMMA AUC0-12 h ratio. CYP2D6 and COMT
genotypes have been recently associated with lower sodium in
plasma and/or higher cortisol levels among MDMA users [37,38].
MDA. Similar plasma concentrations in men and women are
consistent with Kolbrichs results at the 1.6 mg/kg dose [10].
Slightly higher concentrations of MDA observed in women
(Table 3) could be due to the lower CYP2D6 activity that implies
both a higher availability of substrate (MDMA) for N-demethyl-
ation to MDA and a simple accumulation of MDA, since the O-
demethylenation pathway from MDA to HHA is also regulated by
CYP2D6 [21].
Table 5. Genetic differences in physiological and subjective effects after MDMA administration (mean 6 SD; women n= 12 vs.
men n= 15) (only significant effects included).
Genotype AUC 0-4 h (Units) AUC 0–6 h (Units) AUC 0–24 h (Units) Emax (Units)
COMT val158met val/val met/* val/val met/* val/val met/* val/val met/*
SBP 76.8617.9* 47.3623.9 100.4629.5* 60.1632.6 2516128.8** 73.46115.6 34.267.0* 24.468.0
DBP 34.8617.0 22.0618.4 44.4624.8 25.7625.8 1016107.2* 12.4669.8 19.266.5 14.465.6
Dizziness 5.669.3 13.2615.7* 6.5611.6 13.9616.2* 7.1613.3 15.3617.8* 11.7611.5 18.0612.7*
VESSPA – Anxiety 17.566.4 23.0612.9 19.667.7 27.3614.0 21.169.1 30.7616.9* 9.264.7 10.464.8
5-HTTLPR l/* s/s l/* s/s l/* s/s l/* s/s
SBP 65.4624.0** 39.9620.2 85.4634.3** 48.8626.0 1736153.4* 54.0680.9 30.768.1** 21.466.6
DBP 30.4618.0 17.5616.5 37.8624.5 19.1625.5 60.0690.0 4.6681.6 17.466.2** 12.664.4
Heart rate 46.1624.9 33.0625.3 62.7635.6* 36.6635.9 121.9694.8* 17.86146.6 22.069.4 20.7610.5
VESSPA – Sedation 8.869.2 18.8612.1* 11.9611.7 22.6615.6 30.1647.1 30.1635.9 5.964.8 8.264.0
AUC: area under the effect-time curve; Emax: peak effect; COMT, catechol-O-methyltransferase; SBP: systolic blood pressure; DBP: diastolic blood pressure. 5-HTTLPR,
gene-linked polymorphic region VESSPA: Evaluation of the Subjective Effects of Substances with Abuse Potential.
*p,0.05;
**p,0.01. N = [COMT, valval n = 8 vs. met/* n = 18; 5-HTTLPR, l/* n = 18 vs. s/s n = 9.
doi:10.1371/journal.pone.0047599.t005
Figure 1. Plasma Concentrations of MDMA, HMMA, MDA, and HMA in both genders (mean ± standard error of the mean, SEM; for
MDMA and HMMA: women n=11 vs. men n=15; for MDA and HMA: women n=11 vs. men n=12). Influence of CYP2D6 genotype in
plasma concentrations of HMMA (mean 6 SEM; subjects with 2 FA n=18 vs. with 1 FA n=8. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0047599.g001
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Physiological Effects
In the absence of pharmacokinetic differences between the
genders, the most important findings in our study were that female
gender and the 5-HTTLPR and the COMT val158met polymor-
phisms play a major role in modulating the physiological and
subjective effects of MDMA.
The main results show that women presented more intense
effects in SBP, HR, and OT than men, while subjects with high
functionality in 5-HTTLPR (l/* alleles) or COMT val158met (val/val
alleles) genotypes experienced increased cardiovascular effects.
The MDMA-induced cardiovascular effects are mainly due to
the release of NE and 5-HT [39,40]. Gender differences in the 5-
HT neurotransmission system, which is modulated by sex steroids,
could have contributed to our results. Women exhibited an
enhanced serotonergic function in relation to men [15,41]. On the
other hand, men have larger reserves of 5-HT, and, therefore,
more extensive disturbances in 5-HT synthesis/transmission may
be required to respond to MDMA [42].
Genetics determined blood pressure (BP) and HR effects. Our
results are plausible since MDMA promotes 5-HT release through
the translocation of 5-HTT and, as a result, the availability of 5-
HT in the synapse will be greater in the l/* carriers because they
present higher expression of 5-HTT in relation to the s/s carriers.
Furthermore, results of BP according to COMT val158met genotype
are consistent with the literature [43], and independent of BP
results regarding 5-HTTLPR genotype since the proportion of
subjects with l/* and s/s alleles in val/val and met/* groups was
similar.
MDMA-induced effects on HR are determined by female
gender and 5-HTTLPR genotype. However, gender might be
more important than genetics; in fact, women showed higher HR
increases than men in all four subgroups of genotypes (no
differences in HR increase were observed between women
carrying l/* and s/s allelic-variants, results not shown). The
results on HR are clinically relevant because the mean 20 beats/
min (bpm) HR increase developed into tachycardia in some cases.
Furthermore, HR increase would be greater in a real context of
drug consumption than that observed in our laboratory controlled
study because consumers dance for hours under stressful
conditions (loud music and high ambient temperature), and
repeated doses may be taken per session. Globally, this would
worsen observations made in the experimental setting. Naturalistic
studies suggest that the HR of ecstasy users easily reaches
100 bpm. [44,45]. Values that are comparable with those
observed during physical exercise of variable intensity in healthy
people [46,47].
The modest increase observed in OT, which is well-document-
ed, seems to be influenced by gender, although the contribution of
the 5-HTTLPR polymorphism should not be completely discarded
[5,48,30].The sexual dimorphism in the 5-HT system (previously
discussed) may explain gender differences. When comparing OT
values of l/l vs. s/s carriers there were differences in the AUC0-8 h
(p= 0.015) (Figure 2). The increase of OT observed between 8–
12 h post-administration of MDMA could be simply physiological
(circadian rhythm).
In the work of Liechti et al [8] whilst no gender differences were
reported in DBP, HR, and peripheral body temperature they
were, however, observed in SBP where men displayed significantly
higher values. Women showed a significant increase in SBP and
DBP compared to placebo. Discrepant results between our study
and Lietchis could be due to the fact that the volunteers of Liechti
and colleagues were drug naı¨ve, received similar or higher MDMA
doses (1.35–1.8 mg/kg) than ours, and genetic polymorphisms
were not considered.
Figure 2. Influence of gender and genetics (COMT, 5-HTTLPR) on the temporal course of systolic blood pressure (upper-left panel),
heart rate (lower-left panel), and oral temperature (right-end panel) (mean± SEM); women n=12 vs.men n=15; COMT, val/val n=8
vs. met/* n=18; 5-HTTLPR, l/* n=18 vs. s/s n=9). *p,0.05, **p,0.01. Graph A corresponds to gender differences in OT, graph B corresponds to
differences in OT as a function of 5-HTTLPR polymorphisms (l/l n=11 vs. s/s n= 9). Subjects l/s (n = 7) are not represented for graph clarity, but data
almost fully overlaps with the s/s trace.
doi:10.1371/journal.pone.0047599.g002
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Subjective Effects
The main findings are that some negative effects were
modulated by female gender and 5-HTTLPR or COMT val158met
genotypes whereas similar positive effects were observed irrespec-
tive of gender or genotypes.
Women experienced significant effects in dizziness, depression/
sadness and psychotic symptoms, and sedation all of which are
consistent with the literature [45,5,10,21]. The negative subjective
effects observed in women could be due to a higher predisposition
to suffer from psychological/mood disorders than men [49,15].
MDMA may act as a trigger for such symptoms by the depletion of
the limited 5-HT reserves in women. In contrast, men could
compensate for the psychological adverse effects of MDMA
through faster synthesis and larger reserves of 5-HT [50].
The 5-HTTLPR and COMT val158met genotypes with low
functionality also influenced subjective effects. Sedation was
determined by s/s alleles whilst dizziness and anxiety depended
on met/* alleles [15]. A larger number of adverse effects in met/*
carriers have been reported after amphetamine administration
[51].
No gender differences were observed in positive subjective
effects as reported by other authors of psychostimulant studies
[52,45], although some have suggested that this may depend on
the phase of the menstrual cycle [53]. Nevertheless, as far as
MDMA effects are influenced by environment (e.g. increased in a
rave party), gender differences may exist, and the neutral
environment of this experiment should also be considered [45].
A major limitation of the present study was that it was relatively
small considering the large number of statistical tests that were not
corrected for multiple comparisons. Consequently, a larger study is
needed to confirm the findings. The lack of statistical power might
have limited the detection of minor gender differences in MDMA
plasma concentrations. Nonetheless, drugs6gender interaction
findings are independent of CYP2D6, COMT, or 5-HTTLPR
genotype distributions among males and females. Moreover, we
should point out that our drugs6gene interaction findings are in
agreement with initial assumptions, biologically plausible, and
consistent with the previous literature. Therefore, although these
results need to be further explored and replicated, the probability
that they stem from false positive effects is low. Outlying values
were distributed in a similar way between genders and genotypes
and did not contribute to differences observed among experimen-
tal groups. We are aware that our results concern mainly extensive
and intermediate metabolizers of CYP2D6 which represent about
90% of the general population. Extreme phenotypes (poor and
ultrarapid metabolizers) were not included because in the
screening of more than sixty-five subjects, recreational users of
MDMA, genotyped for CYP2D6, these phenotypes were under-
represented. Two poor metabolizers were not considered for their
inclusion due to comorbid psychopathology, and none of the
subjects carried duplications of CYP2D6 functional alleles leading
to the ultrarapid phenotype. Similar findings have been reported
in other series of MDMA users [38]. Apparently, there are fewer
subjects with these extreme phenotypes who consume MDMA in
comparison with the general population. As reported earlier, poor
metabolizer subjects may display increased plasma concentrations
and more intense pharmacological effects after a single dose of
MDMA [12], similar to those experienced by extensive metabo-
lizers after two consecutive doses, because of a phenomenon of
phenocopying towards the poor metabolizer phenotype due to
CYP2D6 autoinhibition. A larger and more comprehensive study
is needed to more conclusively evaluate the effect of CYP2D6
function on the effects of MDMA. In particular, it needs to be
examined whether CYP2D6 poor metabolizers exhibit increased
exposure to MDMA and an enhanced pharmacodynamic
response to the drug.
The large number of statistical tests applied was not corrected.
Although this attitude implies a strong probability of a Type 1
error, lowering the significance level (for example to 0.01) would
have implied an even greater increase of the probability of a Type
2 error because of the small sample size.
At the dose administered (1.4 mg/kg) no major gender
pharmacokinetic differences were reported. They could, however,
be observed with lower (1 mg/kg) [10] doses of MDMA than those
assayed.
In conclusion, there are marked gender differences in MDMA
pharmacology. Women experience greater heightened physiolog-
ical and negative subjective effects than men. This observation
does not appear to be related to gender differences in drug
disposition at the dose assayed of 1.4 mg/kg. The 5-HTTLPR
and/or COMT val158met polymorphisms combine to play an
important role in modulating risk for MDMA adverse effects,
mainly cardiovascular ones.
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